Did UroGen Pharma beat or miss consensus estimates last quarter?

What is the revenue and EPS growth rate for UroGen Pharma year over year?

What were the key takeaways from UroGen Pharma’s earnings call?

What were the key takeaways from UroGen Pharma's earnings call?

What is UroGen Pharma's latest dividend and current dividend yield?

What factors drove the changes in UroGen Pharma's revenue and profit?

What does UroGen Pharma do and what are its main business segments?

What is the market's earnings forecast for UroGen Pharma next quarter?

- **ZUSDURI Early Momentum**: $1.8M Q3 sales, $4.5M October demand revenue, with 45-60 day PEF-to-treatment lag. 
- **JELMYTO Growth**: 13% YoY revenue increase, solidifying as standard of care. 
- **Pipeline Progress**: UGN-103 NDA submission planned for H2 2026, UGN-501 Phase I in 2026. 
- **Financial Health**: $127M cash, 2025 JELMYTO guidance of $94-98M, no immediate capital needs. 
- **Strategic Focus**: Permanent J-code launch in January 2026 to accelerate ZUSDURI adoption.

**【CEO Summary Section】**
- ZUSDURI generated $1.8 million in Q3 2025 sales, with preliminary October demand revenue of $4.5 million, reflecting early momentum. 
- Conversion of patient enrollment forms (PEFs) to actual treatments is delayed due to administrative challenges, averaging 45-60 days post-PEF submission. 
- JELMYTO revenue grew 13% YoY to $25.7 million, driven by price and volume growth. 
- The permanent J-code for ZUSDURI will be effective January 1, 2026, expected to accelerate adoption in community settings. 
- UGN-103 Phase III UTOPIA trial showed a 77.8% complete response rate, consistent with ENVISION data, with NDA submission planned for H2 2026. 

**【CFO Financial Commentary】**
- Total Q3 2025 revenue: $27.5 million (JELMYTO: $25.7 million, ZUSDURI: $1.8 million). 
- R&D expenses: $14 million (up $2.6 million YoY due to UTOPIA trial costs). 
- SG&A expenses: $37.6 million (up $8.7 million YoY due to ZUSDURI commercialization). 
- Net loss: $33.3 million, with cash reserves of $127.4 million. 
- 2025 JELMYTO revenue guidance: $94-98 million (8-12% YoY growth). 
- Full-year 2025 operating expenses: $215-225 million. 

**【Q&A Highlights】**
- **J-code Impact**: Community practices are waiting for the permanent J-code, with ~35-40% of ZUSDURI treatments in community settings vs. 60-65% in hospitals. 
- **PEF Conversion**: Weekly PEF volumes match or exceed JELMYTO levels, but 45-60 day lag persists due to formulary approvals. 
- **Pipeline Progress**: UGN-501 oncolytic virus IND-enabling studies underway, with Phase I planned for 2026. 
- **Cash Position**: Sufficient liquidity to support current operations, but no immediate capital needs anticipated. 
- **Long-Term Outlook**: ZUSDURI peak revenue potential of $1 billion, driven by $5 billion addressable market for low-grade NMIBC.

UroGen Pharma Ltd. (URGN) Q3 2025 Earnings Call Transcript

Jelmyto

Zusduri

URGN

URGN fundamentals

You can ask Aime